RxDoctor Payments Data

Adam Price, MD

Nephrology · Chattanooga, TNNPI 1922485770

Payments from drug & device makers

$3,772in general payments, 2019–2025

Across 173 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$962
  • OPKO Pharmaceuticals, LLC$599
  • Travere Therapeutics, Inc.$408
  • Calliditas Therapeutics US Inc.$386
  • Otsuka America Pharmaceutical, Inc.$311
  • Bayer$239
  • plus $868 from 15 others

What the payments were for

  • Consulting fees$2256%
  • Food & beverage$3,45592%
  • Education$922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,772 in reported general payments places this provider in the 65th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$415,125
Medicare patients
955
Services billed
11,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol61$54,129
Cinacalcet Hcl32$10,330
EliquisApixaban11$6,380
Potassium Chloride107$2,209
Hydralazine Hcl91$1,935
Potassium Citrate ErPotassium Citrate14$1,758
Doxazosin Mesylate106$1,525
Valsartan21$1,493
Allopurinol126$973
Carvedilol118$869
Calcium Acetate13$852
Amlodipine Besylate176$704
Torsemide33$696
Bumetanide17$667
Lisinopril85$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$962$54,12961 claims
ANI Pharmaceuticals, Inc.Valsartan$23$1,49321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →